GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Marksans Pharma Ltd (NSE:MARKSANS) » Definitions » EPS (Diluted)

Marksans Pharma (NSE:MARKSANS) EPS (Diluted) : ₹7.07 (TTM As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Marksans Pharma EPS (Diluted)?

Marksans Pharma's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was ₹1.84. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.07.

Marksans Pharma's EPS (Basic) for the three months ended in Dec. 2023 was ₹1.84. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.07.

Marksans Pharma's EPS without NRI for the three months ended in Dec. 2023 was ₹1.84. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₹7.07.

During the past 12 months, Marksans Pharma's average EPS without NRIGrowth Rate was 35.20% per year. During the past 3 years, the average EPS without NRIGrowth Rate was 32.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was 49.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Marksans Pharma's highest 3-Year average EPS without NRI Growth Rate was 138.30% per year. The lowest was -182.70% per year. And the median was 17.30% per year.


Marksans Pharma EPS (Diluted) Historical Data

The historical data trend for Marksans Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marksans Pharma EPS (Diluted) Chart

Marksans Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.87 2.95 5.83 4.51 6.41

Marksans Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.87 1.52 1.84 1.84

Competitive Comparison of Marksans Pharma's EPS (Diluted)

For the Drug Manufacturers - General subindustry, Marksans Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marksans Pharma's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Marksans Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Marksans Pharma's PE Ratio falls into.



Marksans Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Marksans Pharma's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(2663.08-0)/415.400
=6.41

Marksans Pharma's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(832.35-0)/452.364
=1.84

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹7.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marksans Pharma  (NSE:MARKSANS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Marksans Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Marksans Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Marksans Pharma (NSE:MARKSANS) Business Description

Traded in Other Exchanges
Address
Veera Desai Extension Road, 11th Floor, Grandeur, Opposite Gundecha Symphony, Oshiwara, Andheri (West), Mumbai, MH, IND, 400053
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal and oncologic drugs as well as antibiotics and antiallergic medications. It has a market presence with the majority of the revenue generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, India, and the Rest of the World.

Marksans Pharma (NSE:MARKSANS) Headlines

No Headlines